Peptide research is not one-size-fits-all. Women metabolize compounds differently, have distinct hormonal cycles, and face conditions (like HSDD, postmenopausal bone loss, and hormonal acne) that men do not. This guide pulls the most relevant compounds from across the Peptexa library and rates them specifically by the strength of evidence in female populations where that data exists. PT-141 (Vyleesi) is the only peptide in this entire guide that is FDA-approved specifically for women. Everything else ranges from strong general evidence to early research.
Important: Star ratings measure evidence strength, not safety.
Every compound in this category, ranked by evidence strength.
| Peptide | FDA Status | Evidence | Key Note |
|---|---|---|---|
| PT-141 / Bremelanotide (Vyleesi) | FDA-Approved (women) | ★★★★☆ | Approved for premenopausal female HSDD |
| Semaglutide (Wegovy) | FDA-Approved | ★★★★★ | Strong weight loss data in women; STEP trials |
| Tirzepatide (Zepbound) | FDA-Approved | ★★★★★ | Superior weight loss vs semaglutide; SURMOUNT data |
| GHK-Cu | Cosmetic / Research | ★★★★☆ / ★★☆☆☆ | Strong topical evidence for skin; systemic use preclinical |
| Matrixyl (Palmitoyl Pentapeptide) | Cosmetic | ★★★☆☆ | Clinical skincare studies support anti-wrinkle effects |
| Collagen Peptides | Dietary Supplement | ★★★★☆ | Strong oral evidence for skin, hair, joint health |
| Epithalon | Research | ★★☆☆☆ | Russian clinical data on telomere activation; limited Western studies |
| Kisspeptin | Research | ★★★☆☆ | Studied for female reproductive hormone regulation |
| Oxytocin | FDA-Approved (obstetric) | ★★★★☆ / ★★☆☆☆ | Approved for labor induction; off-label bonding/libido use weakly evidenced |
| Selank | Approved in Russia | ★★★☆☆ | Anxiolytic peptide; Russian approval for anxiety |
| DSIP | Research | ★★☆☆☆ | Studied since 1970s for sleep; inconsistent results |
| BPC-157 | Research | ★★☆☆☆ | Strong animal gut-healing data; limited human evidence |
| Thymosin Beta-4 | Research | ★★☆☆☆ | Wound healing and tissue repair; primarily preclinical |
| AOD-9604 | Research | ★★☆☆☆ | Failed Phase IIb for weight loss |
| Argireline | Cosmetic | ★★★☆☆ | Topical anti-wrinkle; some clinical cosmetic studies |
The only peptide in this guide FDA-approved specifically for a female condition. Bremelanotide (Vyleesi) targets melanocortin receptors in the brain to address hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike ED drugs that work through blood flow, PT-141 works through desire pathways. Administered as a self-injection before anticipated activity. Common side effects include nausea and flushing.
The GLP-1 agonists have strong data in women specifically. The STEP and SURMOUNT trials enrolled significant female populations. Weight loss results are comparable between sexes. Both are prescription medications requiring medical supervision. Tirzepatide shows slightly stronger results in head-to-head comparisons.
Copper peptide with robust evidence for topical skin applications: wound healing, collagen stimulation, and anti-aging effects. Popular in women's skincare. The split rating matters: topical use has clinical backing, but injectable/systemic use for anti-aging is primarily preclinical.
One of the most well-evidenced compounds for women's health concerns. Multiple RCTs support oral collagen for skin elasticity, nail strength, hair thickness, and joint health. Accessible as a supplement without prescription. Evidence is strongest for skin and joint benefits.
A reproductive hormone regulator being studied for fertility, PCOS, and hypothalamic amenorrhea. Early human studies in women show it can stimulate luteinizing hormone release. Still investigational but one of the more promising peptides for female-specific reproductive health.
Every compound in this category, fully profiled with mechanisms, evidence ratings, FDA status, and research citations.
Get the Complete Collection Guide, $19.99 →One-time purchase. Instant download. No subscription.